Original Paper

Digestive Diseases and Sciences

, Volume 53, Issue 10, pp 2714-2718

Therapeutic Effect of Lactobacillus acidophilus-SDC 2012, 2013 in Patients with Irritable Bowel Syndrome

  • Dong Hyun SinnAffiliated withDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • , Ji Hyun SongAffiliated withHealthcare System, Gangnam Center, Seoul National University Hospital
  • , Hoi Jin KimAffiliated withDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • , Jun Haeng LeeAffiliated withDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • , Hee Jung SonAffiliated withDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • , Dong Kyung ChangAffiliated withDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • , Young-Ho KimAffiliated withDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • , Jae J. KimAffiliated withDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • , Jong Chul RheeAffiliated withDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
    • , Poong-Lyul RheeAffiliated withDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of MedicineDivision of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Probiotic bacteria exhibit a variety of properties, which are unique to a particular strain. Lactobacillus acidophilus-SDC 2012, 2013 are new strains isolated from Korean infants’ feces. The potential utility of Lactobacillus acidophilus-SDC 2012, 2013 in irritable bowel syndrome (IBS) was studied. Forty IBS patients were randomized into a placebo (n = 20) and probiotics group (n = 20). Four weeks of treatment with L. acidophilus-SDC 2012, 2013 was associated with a reduced score for abdominal pain or discomfort compared to the baseline (P = 0.011). The percent reduction in abdominal pain or discomfort exceeded the placebo scores by more than 20% (23.8 and 0.2% for probiotics and placebo, respectively, P = 0.003). There was a significant difference in the proportion of responders between the probiotics and placebo groups (P = 0.011). There was no drop out or adverse events for either group during the study period. Lactobacillus acidophilus-SDC 2012, 2013 appeared to have a beneficial effect in patients with IBS. Further studies are warranted.

Keywords

Probiotics Irritable bowel syndrome Lactobacillus acidophilus